Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Tsutsumi, Yasuo M ^a   Tsutsumi, Rie ^a   Hamaguchi, Eisuke ^a   Sakai, Yoko ^a   Kasai, Asuka ^a   Ishikawa, Yoshihiro ^b   Yokoyama, Utako ^b   Tanaka, Katsuya ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cardiac protection; Glucagon like peptide 1 receptor; Incretin; Subcellular microdomain

Indexed keywords

CAVEOLIN 3; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; METHYL BETA CYCLODEXTRIN; TROPONIN I; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CAVEOLA; CELL DEATH; CELL FRACTIONATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; RAT; REPERFUSION INJURY; SUCROSE DENSITY GRADIENT CENTRIFUGATION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; DRUG EFFECTS; ISCHEMIA; METABOLISM; MYOCARDIAL REPERFUSION INJURY; WISTAR RAT;

ANIMALS; CAVEOLAE; CAVEOLIN 3; HYPOGLYCEMIC AGENTS; ISCHEMIA; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PEPTIDES; RATS, WISTAR; VENOMS;

EID: 84964812082     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0132-9     Document Type: Article

References (52)

1. Drucker DJ: The biology of incretin hormones. Cell Metab 2006, 3(3):153-165.
2. Davidson MH: Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011, 108(3 Suppl):33B-41B.
3. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157.
4. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-2350.
5. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54(1):146-151.
6. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58(4):975-983.
7. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE: Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53(6):501-510.
8. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267(11):7402-7405.
9. Sonne DP, Engstrom T, Treiman M: Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146(1-3):243-249.
10. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M: Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151(4):1520-1531.
11. Stary CM, Tsutsumi YM, Patel PM, Head BP, Patel HH, Roth DM: Caveolins: targeting pro-survival signaling in the heart and brain. Front Physiol 2012, 3:393.
12. Insel PA, Head BP, Ostrom RS, Patel HH, Swaney JS, Tang CM, Roth DM: Caveolae and lipid rafts: G protein-coupled receptor signaling microdomains in cardiac myocytes. Ann N Y Acad Sci 2005, 1047:166-172.
13. Patel HH, Murray F, Insel PA: G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb Exp Pharmacol 2008, 186:167-184.
14. Tsutsumi YM, Horikawa YT, Jennings MM, Kidd MW, Niesman IR, Yokoyama U, Head BP, Hagiwara Y, Ishikawa Y, Miyanohara A, Patel PM, Insel PA, Patel HH, Roth DM: Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 2008, 118(19):1979-1988.
15. Horikawa YT, Patel HH, Tsutsumi YM, Jennings MM, Kidd MW, Hagiwara Y, Ishikawa Y, Insel PA, Roth DM: Caveolin-3 expression and caveolae are required for isoflurane-induced cardiac protection from hypoxia and ischemia/reperfusion injury. J Mol Cell Cardiol 2008, 44(1):123-130.
16. Tsutsumi YM, Kawaraguchi Y, Horikawa YT, Niesman IR, Kidd MW, Chin-Lee B, Head BP, Patel PM, Roth DM, Patel HH: Role of caveolin-3 and glucose transporter-4 in isoflurane-induced delayed cardiac protection. Anesthesiology 2010, 112(5):1136-1145.
17. Tsutsumi YM, Kawaraguchi Y, Niesman IR, Patel HH, Roth DM: Opioid-induced preconditioning is dependent on caveolin-3 expression. Anesth Analg 2010, 111(5):1117-1121.
18. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8(6):e1000412.
19. Hagiwara Y, Sasaoka T, Araishi K, Imamura M, Yorifuji H, Nonaka I, Ozawa E, Kikuchi T: Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet 2000, 9(20):3047-3054.
20. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology 2000, 92(4):1154-1159.
21. Kawano T, Oshita S, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Takahashi A, Nakaya Y: Clinically relevant concentrations of propofol have no effect on adenosine triphosphate-sensitive potassium channels in rat ventricular myocytes. Anesthesiology 2002, 96(6):1472-1477.
22. Patel HH, Tsutsumi YM, Head BP, Niesman IR, Jennings M, Horikawa Y, Huang D, Moreno AL, Patel PM, Insel PA, Roth DM: Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. FASEB J 2007, 21(7):1565-1574.
23. Tsutsumi YM, Tsutsumi R, Horikawa YT, Sakai Y, Hamaguchi E, Ishikawa Y, Yokoyama U, Kasai A, Kambe N, Tanaka K: Geranylgeranylacetone protects the heart via caveolae and caveolin-3. Life Sci 2014, 101(1-2):43-48.
24. Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y, Kinoshita M, Tanaka K, Oshita S: Compound K, a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Life Sci 2011, 88(15-16):725-729.
25. Tsutsumi YM, Patel HH, Lai NC, Takahashi T, Head BP, Roth DM: Isoflurane produces sustained cardiac protection after ischemia-reperfusion injury in mice. Anesthesiology 2006, 104(3):495-502.
26. Hirose K, Tsutsumi YM, Tsutsumi R, Shono M, Katayama E, Kinoshita M, Tanaka K, Oshita S: Role of the O-linked beta-N-acetylglucosamine in the cardioprotection induced by isoflurane. Anesthesiology 2011, 115(5):955-962.
27. Tsutsumi YM, Patel HH, Huang D, Roth DM: Role of 12-lipoxygenase in volatile anesthetic-induced delayed preconditioning in mice. Am J Physiol Heart Circ Physiol 2006, 291(2):H979-H983.
28. Tsutsumi YM, Yokoyama T, Horikawa Y, Roth DM, Patel HH: Reactive oxygen species trigger ischemic and pharmacological postconditioning: In vivo and in vitro characterization. Life Sci 2007, 81(15):1223-1227.
29. Green BD, Flatt PR, Bailey CJ: Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006, 3(3):159-165.
30. Bose AK, Mocanu MM, Carr RD, Yellon DM: Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21(4):253-256.
31. Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM: Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol 2013, 12(1):154.
32. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM: Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol 2013, 12:148.
33. Syme CA, Zhang L, Bisello A: Caveolin-1 regulates cellular trafficking and function of the glucagon-like Peptide 1 receptor. Mol Endocrinol 2006, 20(12):3400-3411.
34. Yang Y, Tong Y, Gong M, Lu Y, Wang C, Zhou M, Yang Q, Mao T, Tong N: Activation of PPARbeta/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor. Cell Signal 2014, 26(2):268-278.
35. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110(1):43-52.
36. Gardiner SM, March JE, Kemp PA, Bennett T, Baker DJ: Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats. Br J Pharmacol 2010, 161(1):92-102.
37. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996, 271(3 Pt 1):E458-E464.
38. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, Gutniak M: Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24(4):569-578.
39. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359(9309):824-830.
40. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298(2):194-206.
41. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705.
42. Inzucchi SE, McGuire DK: New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 2008, 117(4):574-584.
43. Bose AK, Mocanu MM, Carr RD, Yellon DM: Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005, 19(1):9-11.
44. Gardiner SM, March JE, Kemp PA, Bennett T: Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006, 316(2):852-859.
45. Barragan JM, Eng J, Rodriguez R, Blazquez E: Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999, 277(5 Pt 1):E784-E791.
46. Deacon CF: Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004, 36(11-12):761-765.
47. Nikolaidis LA, Elahi D, Shen YT, Shannon RP: Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289(6):H2401-H2408.
48. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP: Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 2002, 277(41):38988-38997.
49. Oshikawa J, Otsu K, Toya Y, Tsunematsu T, Hankins R, Kawabe J, Minamisawa S, Umemura S, Hagiwara Y, Ishikawa Y: Insulin resistance in skeletal muscles of caveolin-3-null mice. Proc Natl Acad Sci U S A 2004, 101(34):12670-12675.
50. Meloni AR, DeYoung MB, Han J, Best JH, Grimm M: Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol 2013, 12:48.
51. Lonborg J, Vejlstrup N, Kelbaek H, Nepper-Christensen L, Jorgensen E, Helqvist S, Holmvang L, Saunamaki K, Botker HE, Kim WY, Clemmensen P, Treiman M, Engstorm T: Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study. Diabetes 2014, 63(7):2474-2485.
52. Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, Goeke B, Marx N, Parhofer KG, Lehrke M: Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol 2013, 12:117.